<PAGE>
FILED PURSUANT TO RULE 424(b)(3)
REGISTRATION NO. 333-47267
PROSPECTUS
CONCENTRA MANAGED CARE, INC.
4,082,897 SHARES OF COMMON STOCK
THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND
EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION NOR HAS THE
SECURITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION
PASSED UPON THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY
REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.
----------
This Prospectus relates to the offering from time to time by certain
stockholders of the Company or any donee, transferree, assignee or other
successor in interest of any such stockholder identified under "Selling
Stockholders" (collectively, the "Selling Stockholders") of up to an
aggregate of 4,082,897 shares of common stock, par value $.01 per share
("Common Stock"), of Concentra Managed Care, Inc., a Delaware corporation
("Concentra" or the "Company"). The shares of Common Stock offered hereby
(the "Offered Securities") were privately offered by the Company in
connection with the acquisition of all of the outstanding capital stock of
Preferred Payment Systems, Inc. ("PPS") that occurred on February 24, 1998 as
a result of the merger of a direct wholly-owned subsidiary of Concentra with
and into PPS (the "PPS Transaction"). The total consideration paid was
approximately $257 million, consisting of 7,100,690 shares of Common Stock
and $14.7 million in cash. Pursuant to the Registration Rights Agreement
dated February 24, 1998, by and among the Company and each of the Selling
Stockholders (the "PPS Registration Rights Agreement"), the Company agreed to
register 4,082,897 shares of the total number of shares issued to the Selling
Stockholders in the PPS Transaction. See "Selling Stockholders" and "Plan of
Distribution" for information relating to the Selling Stockholders and this
offering.
The Offered Securities may be sold from time to time pursuant to this
Prospectus by the Selling Stockholders. The Offered Securities may be sold by
the Selling Stockholders in ordinary brokerage transactions, in transactions
in which brokers solicit purchases, in negotiated transactions, or in a
combination of such methods of sale, at market prices prevailing at the time
of sale, at prices relating to such prevailing market prices or at negotiated
prices. See "Plan of Distribution." The distribution of the Offered
Securities is not subject to any underwriting agreement. The Company will
receive no part of the proceeds of sales from the offering by the Selling
Stockholders. All expenses of registration incurred in connection with this
offering are being borne by the Company. None of the Offered Securities have
been registered prior to the filing of the Registration Statement of which
this Prospectus is a part.
The Common Stock is traded on the Nasdaq National Market under the
symbol "CCMC." On March 12, 1998, the last reported sale price of the
Common Stock on The Nasdaq National Market was $31 5/8 per share.
----------
The date of this Prospectus is March 12, 1998
<PAGE>
AVAILABLE INFORMATION
The Company is subject to the informational requirements of the Securities
Exchange Act of 1934 (the "Exchange Act"). In accordance with the Exchange Act,
the Company files reports, proxy statements and other information with the
Securities and Exchange Commission (the "Commission"). Those reports, proxy
statements and other information can be inspected and copied at the public
reference facilities that the Commission maintains at Room 1024, 450 Fifth
Street, N.W., Washington, D.C. 20549, and at the Commission's regional offices
located at 7 World Trade Center, 13th Floor, New York, New York 10048, and 500
West Madison Street, Suite 1400, Chicago, Illinois 60661. Copies of these
materials can be obtained at prescribed rates from the Public Reference Section
of the Commission at the principal offices of the Commission, 450 Fifth Street,
N.W., Washington, D.C. 20549. These reports, proxy statements and other
information may also be obtained without charge from the web site that the
Commission maintains at http:\\www.sec.gov. These reports, proxy statements and
other information also may be inspected at the offices of the Nasdaq Stock
Market, Inc., 1735 K Street, NW, Washington, DC 20006.
The Company has filed with the Commission a registration statement on Form
S-3 (herein, together with all amendments and exhibits, referred to as the
"Registration Statement") under the Securities Act of 1933 (the "Securities
Act"), with respect to the Offered Securities. This Prospectus and any
accompanying prospectus supplement do not contain all of the information set
forth in the Registration Statement, certain parts of which are omitted in
accordance with the rules and regulations of the Commission. For further
information with respect to the Company and the Offered Securities, reference is
made to the Registration Statement and to the exhibits thereto. Statements
contained herein concerning the provisions of certain documents are not
necessarily complete, and in each instance, reference is made to the copy of the
document filed as an exhibit to the Registration Statement or otherwise filed
with the Commission. Each such statement is qualified in its entirety by that
reference.
----------------------
INCORPORATION OF CERTAIN INFORMATION BY REFERENCE
The following documents filed by the Company with the Commission pursuant
to the Exchange Act are incorporated in this Prospectus by reference:
1. The Company's Registration Statement on Form S-4 (File No. 333-27105)
dated August 1, 1997;
2. The Company's Quarterly Report on Form 10-Q for the quarter ended
September 30, 1997;
3. The Company's Current Reports on Form 8-K filed on September 11, 1997,
October 1, 1997, October 14, 1997, November 7, 1997, January 23, 1998,
February 2, 1998, February 18, 1998, March 2, 1998 and March 11,
1998; and
4. The description of the Company's capital stock contained in Item 1 of
the Registration Statement on Form 8-A (File No. 000-22751) filed with
the Commission on June 25, 1997, including any amendment or report
filed for the purpose of updating such description filed with the
Commission pursuant to Section 13 of the Exchange Act.
All other documents filed by the Company pursuant to Sections 13(a), 13(c),
14 or 15(d) of the Exchange Act after the date of this Prospectus and prior to
the filing of a post-effective amendment which indicates that all securities
offered have been sold or which deregisters all securities then remaining
unsold, shall be deemed to be incorporated by reference in this Prospectus and
to be a part hereof from the date of filing such documents.
The Company will provide without charge to each person to whom a copy of
this Prospectus is delivered, upon the written or oral request of any such
person, a copy of any or all of the documents that are incorporated by
reference, other than exhibits to such documents not specifically incorporated
by reference. Requests for such copies should be directed to Concentra Managed
Care, Inc., 5080 Spectrum Drive, Suite 400, West Tower, Dallas, Texas 75248,
Attention: Richard A. Parr II, Executive Vice President and General Counsel,
telephone (972) 364-8000.
2
<PAGE>
Any statement contained in a document incorporated by reference herein
shall be deemed to be modified or superseded for purposes of this Prospectus to
the extent that a statement contained herein modifies or supersedes such
statement. Any such statement so modified or superseded shall not be deemed,
except as so modified or superseded, to constitute a part of this Prospectus.
THE COMPANY
Concentra is a comprehensive outsourcing solution for cost containment and
health management in group healthcare, property and casualty, and occupational
medicine. Concentra offers prospective services to employers and insurers of
all sizes, providing pre-employment testing, loss prevention services, first
report of injury, injury care, specialist networks and specialized cost
containment to the disability and automobile injury markets. The Company has
123 field case management offices, with approximately 1,350 field case managers
who provide medical management and return to work services in 49 states, the
District of Columbia and Canada. The Company also has 83 service locations that
offer specialized cost containment services including utilization management,
telephonic case management, and retrospective bill review. Under the name
Concentra Medical Centers, the Company operates the nation's largest network of
occupational healthcare centers, currently managing the practices of
255 physicians located in 142 centers in 37 markets in 20 states.
The Company's executive offices are located at 312 Union Wharf, Boston,
Massachusetts 02109, and its telephone number at that address is (617) 367-2163.
RISK FACTORS
IN EVALUATING AN INVESTMENT IN SHARES OF COMMON STOCK OF THE COMPANY,
PROSPECTIVE INVESTORS SHOULD CONSIDER CAREFULLY, AMONG OTHER THINGS, THE RISK
FACTORS SET FORTH IN "RISK FACTORS AND CERTAIN CONSIDERATIONS" CONTAINED IN THE
COMPANY'S JOINT PROXY STATEMENT/PROSPECTUS DATED AUGUST 1, 1997, WHICH
CONSTITUTES A PART OF THE REGISTRATION STATEMENT ON FORM S-4 (FILE NO.
333-27105), TOGETHER WITH ALL AMENDMENTS THERETO, THAT THE COMPANY INITIALLY
FILED WITH THE COMMISSION ON MAY 14, 1997.
FORWARD LOOKING STATEMENTS
Statements contained in this Prospectus (including certain of the documents
incorporated by reference herein) that are not based on historical facts are
forward-looking statements subject to uncertainties and risks including, but not
limited to, product and service demand and acceptance, the availability of
appropriate acquisition and joint venture candidates, economic conditions, the
impact of competition and pricing, capacity and supply constraints or
difficulties, results of financing efforts, and other risks described in this
Prospectus (including certain of the documents incorporated by reference
herein).
3
<PAGE>
SELLING STOCKHOLDERS
The following table sets forth the name of the Selling Stockholders and
(i) the number of shares of Common Stock owned by the Selling Stockholders as
of the effective date of the Registration Statement of which this Prospectus
forms a part, (ii) the maximum number of shares of Common Stock which may be
offered for the account of the Selling Stockholders under this Prospectus,
and (iii) the amount and percentage of Common Stock to be owned by the
Selling Stockholders after the completion of this offering assuming the sale
of all the Common Stock which may be offered hereunder. Each of the Selling
Stockholders named below was formerly a stockholder of PPS or a donee,
transferree, assignee or other successor in interest of any such Selling
Stockholder, and acquired the shares of the Company's Common Stock offered
hereby as a result of the PPS Transaction. Except as set forth below, no
Selling Stockholder has had any position, office or other material
relationship with the Company or any of its predecessors within the past
three years. In addition, certain of the Selling Stockholders are venture
capital funds or partnerships which may, in the future, distribute their
shares to their shareholders, members, partners or limited partners and those
shares may later be sold by those shareholders, members, partners or limited
partners.
<TABLE>
AMOUNT AND
MAXIMUM PERCENTAGE OF
NUMBER OF COMMON STOCK
SHARES OWNED SHARES OWNED AFTER THE OFFERING
PRIOR TO WHICH MAY BE ------------------------
SELLING STOCKHOLDERS OFFERING SOLD HEREUNDER AMOUNT PERCENTAGE
- ----------------------------------------- ------------ -------------- ---------- ------------
<S> <C> <C> <C> <C>
Advent VII, L.P.(1) 1,601,081 1,280,865 320,216 *
Advent Atlantic and Pacific III L.P.(1) 927,111 741,689 185,422 *
Advent New York L.P.(1) 160,053 128,043 32,011 *
TA Venture Investors Limited
Partnership(1) 33,752 27,002 6,750 *
Donna Ambrosino 6,088 3,501 2,587 *
Thomas Bartlett(2) 26,473 11,323 15,150 *
Sonny Bloom(3) 60,296 25,789 34,507 *
Joan Bottigliero 3,044 1,750 1,294 *
Chad Charles 2,382 1,370 1,012 *
Craig W. Cunningham(4) 197,047 84,279 112,768 *
James T. Doody(5) 608,891 260,427 348,464 *
Donald A. Gieser 6,088 3,501 2,587 *
Don P. Greenberg(6) 1,193,876 510,631 683,245 *
Trust for Daniel Greenberg 34,174 19,650 14,524 *
Trust for David Greenberg 34,174 19,650 14,524 *
Trust for Robert Greenberg 34,174 19,650 14,524 *
Trust for Amy Greenberg 34,174 19,650 14,524 *
Mary Jane Labelle 5,824 3,349 2,475 *
Zan Larsen 6,088 3,501 2,587 *
Patricia Loid 3,573 2,054 1,519 *
Daniel Marion 23,296 13,395 9,901 *
Brian Masters 3,706 2,131 1,575 *
Steven E. Nelson(7) 1,336,912 571,808 765,104 *
Thomas Nolte 3,706 2,131 1,575 *
Kimberly Pritchett 6,088 3,501 2,587 *
Janet Rancati 6,088 3,501 2,587 *
Byron W. Smith(8) 608,891 260,427 348,464 *
Timothy C. Smith(9) 125,698 53,762 71,936 *
William Zaun 7,942 4,567 3,375 *
------------ -------------- ---------- ------------
Total: 7,100,690 4,082,897 3,017,794 *
</TABLE>
- -------------------------
* Less than 1%
(1) Advent VII L.P., Advent Atlantic and Pacific III, L.P., Advent New York
L.P. and TA Venture Investors Limited Partnership are part of an
affiliated group of investment partnerships. The general partner of
Advent VII, L.P. is TA Associates VII, L.P. The general partner of Advent
Atlantic and Pacific III, L.P. is TA Associates AAP III Partners. The
general partner of Advent New York L.P. is TA Associates VI L.P. The
general partner of each of TA Associates VII, L.P., TA Associates AAP III
Partners and TA Associates VI L.P. is TA Associates, Inc. In such
capacity, TA Associates, Inc. exercises sole voting and investment power
with respect to all of the shares held of record by the named investment
partnerships, with the exception of those shares held by TA Venture
Investors Limited Partnership; individually no stockholder, director or
officer of TA Associates, Inc. is deemed to have or share such voting or
investment power. Principals and employees of TA Associates, Inc.
comprise the general partners of TA Ventrue Investors Limited
Partnership. Richard Tadler, a managing director of TA Associates, Inc.,
and Jonathan Goldstein, a principal of TA Associates, Inc., served as
directors of PPS prior to the consummation of the PPS Transaction.
(2) Upon consummation of the PPS Transaction, Mr. Bartlett was named Vice
President--Marketing of the surviving corporation, Concentra PPS, Inc.
("Concentra PPS"). Mr. Bartlett was formerly Senior Vice President--
Marketing of PPS.
(3) Upon consummation of the PPS Transaction, Mr. Bloom was named Vice
President--Operations and Professional Negotiating Services of Concentra
PPS. Mr. Bloom was formerly Senior Vice President--Negotiating Services,
Rockville of PPS.
(4) Upon consummation of the PPS Transaction, Mr. Cunningham was named Vice
President--Operations of Concentra PPS. Mr. Cunningham was formerly Senior
Vice President--Operations of PPS.
(5) Upon consummation of the PPS Transaction, Mr. Doody was named Senior Vice
President--Sales of Concentra PPS. Mr. Doody was formerly Executive Vice
President--Corporate Sales and a director of PPS.
(6) Upon consummation of the PPS Transaction, Mr. Greenberg was named
Senior Vice President--Medical Director of Concentra PPS. Mr. Greenberg
was formerly Executive Vice President, Chief Operating Officer and a
director of PPS.
(7) Upon consummation of the PPS Transaction, Mr. Nelson was named President
of Concentra PPS. Mr. Cunningham was formerly Chairman of the Board,
President and Chief Executive Officer of PPS.
(8) Upon consummation of the PPS Transaction, Mr. Smith was named Senior Vice
President--Product Development of Concentra PPS. Mr. Cunningham was
formerly Executive Vice President, Chief Technology Officer and a director
of PPS.
(9) Upon consummation of the PPS Transaction, Mr. Smith was named Vice
President--Sales of Concentra PPS. Mr. Smith was formerly Senior Vice
President--Sales of PPS.
4
<PAGE>
PLAN OF DISTRIBUTION
The Offered Securities were issued to the Selling Stockholders in
connection with the PPS Transaction. Pursuant to the PPS Registration Rights
Agreement, the Company agreed to register 4,082,897 shares of the total number
of shares issued to the Selling Stockholders in the PPS Transaction. The
Registration Statement of which this Prospectus forms a part has been filed
pursuant to the PPS Registration Rights Agreement.
The Offered Securities may be sold from time to time directly by the
Selling Stockholders; provided, however, that certain Selling Stockholders
who were formerly affiliates of PPS (as such term is used in and for purposes
of Accounting Series Releases 130 and 135, as amended of the Commission) have
agreed with the Company that they will not sell or dispose of any shares of
Common Stock that they own until the first date on which the Company publicly
releases financial statements that include at least thirty days of
post-merger combined operating results of the Company and PPS; provided,
however, that they may sell up to 10% of their Common Stock during such
period so long as the aggregate of such sales do not exceed 1% of the
Company's total outstanding shares of Common Stock. The Offered Securities
may also be sold by the Selling Stockholders in (a) ordinary brokerage
transactions and in transactions in which brokers solicit purchasers, (b)
sales to a broker or dealer as principal and resales by such broker or dealer
for its own account pursuant to this Prospectus or (c) in a combination of
such methods of sale, at market prices and other terms prevailing at the time
of sale, at prices related to such prevailing market prices or at negotiated
prices. The Offered Securities may be sold on any national securities
exchange or automated interdealer quotation system on which shares of Common
Stock are then listed, through negotiated transactions or otherwise. In
addition, certain of the Selling Stockholders are venture capital funds or
partnerships which may, in the future, distribute their shares to their
sharesholders, members partners or limited partners. Those shares may be
later sold by those shareholders, members partners or limited partners. At
the time a particular offer of any of the Offered Securities is made by the
Selling Stockholders, to the extent required pursuant to the Securities Act,
a supplement to this Prospectus will be distributed which describes the
method of sale in greater detail. In addition, any Offered Securities which
qualify for sale pursuant to Rule 144 under the Securities Act may be sold
under Rule 144 rather than pursuant to this Prospectus.
In connection with the distributions of the shares of Common Stock or
otherwise, the Selling Stockholders may enter into hedging transactions with
broker-dealers. In connection with such transactions, broker-dealers may engage
in short sales of the shares of Common Stock registered hereunder in the course
of hedging the positions they assume with Selling Stockholders. The Selling
Stockholders may also sell shares of Common Stock short and redeliver the shares
to close out such short positions. The Selling Stockholders may also enter into
option or other transactions with broker-dealers which require the delivery to
the broker-dealer of the shares of Common Stock registered hereunder, which the
broker-dealer may resell or otherwise transfer pursuant to this Prospectus.
Brokers, dealers and agents who participate in the sale of the Offered
Securities may receive compensation in the form of underwriting discounts,
concessions or commissions from the Selling Stockholders and/or purchasers of
the Offered Securities for whom they may act as agent. The Selling Stockholders
and any brokers, dealers or agents that participate in the distribution of the
Offered Securities might be deemed to be "underwriters" within the meaning of
the Securities Act, and any profit on the sale of such Offered Securities and
any discounts, commissions or concessions received by any such brokers, dealers
or agents might be deemed to be underwriting discounts and commissions under the
Securities Act. Pursuant to the provisions of the PPS Registration Rights
Agreement, the Selling Stockholders have agreed to pay their costs and expenses
of selling the shares of Common Stock offered hereunder, including commissions
and discounts of underwriters, brokers, dealers or agents, and the Company has
agreed to pay the costs and expenses incident to its registration and
qualification of the Common Stock offered hereby, including registration and
filing fees. In addition the Company has agreed to indemnify the Selling
Stockholders against certain liabilities, including liabilities arising under
the Securities Act. The Selling Stockholders may indemnify any broker-dealer
that participates in transactions involving the sale of shares of Common Stock
against certain liabilities, including liabilities under the Securities Act.
The Company will not receive any of the proceeds from the sale of any of the
Offered Securities by the Selling Stockholders.
There can be no assurance that the Selling Stockholders will sell any or
all of the shares of Common Stock offered by them hereunder.
5
<PAGE>
USE OF PROCEEDS
The Company will not receive any of the proceeds from the sale of the
Offered Securities by the Selling Stockholders.
LEGAL MATTERS
The validity of the Common Stock offered hereby has been passed upon for
the Company by Richard A. Parr II, Executive Vice President and General Counsel
of the Company.
EXPERTS
The consolidated financial statements of OccuSystems, Inc. as of December
31, 1996 and 1995 and for each of the three years in the period ended December
31, 1996, incorporated herein by reference to the Company's Registration
Statement on Form S-4 (File No. 333-27105) dated August 1, 1997, have been so
incorporated in reliance on the report of Arthur Andersen LLP, independent
public accountants, given on the authority of said firms as experts in auditing
and accounting.
The consolidated financial statements of CRA Managed Care, Inc. at December
31, 1996 and 1995 and for each of the three years in the period ended December
31, 1996, incorporated by reference herein by reference to the Company's
Registration Statement on Form S-4 (File No. 333-27105) dated August 1, 1997,
have been so incorporated in reliance on the report of Arthur Andersen LLP,
independent public accountants, given upon the authority of such firm as experts
in accounting and auditing.
6
<PAGE>
- -------------------------------------------------------------------------------
- -------------------------------------------------------------------------------
NO DEALER, SALESPERSON OR OTHER PERSON HAS BEEN AUTHORIZED TO GIVE ANY
INFORMATION OR TO MAKE ANY REPRESENTATIONS OTHER THAN THOSE CONTAINED IN THIS
PROSPECTUS AND, IF GIVEN OR MADE, SUCH INFORMATION OR REPRESENTATIONS MUST
NOT BE RELIED UPON AS HAVING BEEN AUTHORIZED BY THE COMPANY OR ANY OF THE
UNDERWRITERS. THIS PROSPECTUS DOES NOT CONSTITUTE AN OFFER TO SELL OR A
SOLICITATION OF AN OFFER TO BUY THE SHARES BY ANYONE IN ANY JURISDICTION IN
WHICH SUCH OFFER OR SOLICITATION IS NOT AUTHORIZED, OR IN WHICH THE PERSON
MAKING THE OFFER OR SOLICITATION IS NOT QUALIFIED TO DO SO, OR TO ANY PERSON
TO WHOM IT IS UNLAWFUL TO MAKE SUCH OFFER OR SOLICITATION. NEITHER THE
DELIVERY OF THIS PROSPECTUS NOR ANY SALE MADE HEREUNDER SHALL CREATE ANY
IMPLICATION THAT THE INFORMATION CONTAINED HEREIN IS CORRECT AS OF ANY TIME
SUBSEQUENT TO ITS DATE.
----------
TABLE OF CONTENTS
Available Information. . . . . . . . . . . . . . . . . . . . . . . . . . . . .3
Incorporation of Certain Information by Reference. . . . . . . . . . . . . . .3
The Company. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .4
Risk Factors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .4
Forward Looking Statements . . . . . . . . . . . . . . . . . . . . . . . . . .4
Selling Stockholders . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5
Plan of Distribution . . . . . . . . . . . . . . . . . . . . . . . . . . . . .6
Use of Proceeds. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .6
Legal Matters. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .6
Experts. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .6
- -------------------------------------------------------------------------------
- -------------------------------------------------------------------------------
- -------------------------------------------------------------------------------
- -------------------------------------------------------------------------------
4,082,897 SHARES
CONCENTRA MANAGED CARE, INC.
COMMON STOCK
--------------
PROSPECTUS
--------------
MARCH 12, 1998
- -------------------------------------------------------------------------------
- -------------------------------------------------------------------------------
